Although the risk of incident hematological cancer is estimated as 10-fold higher for mosaic than for non-mosaic subjects (95% CI=5.8 – 17.7), it is important to note that the incidence rate in mosaics is low (10 year event rate of 0.143, 95% CI=0.065 – 0.214, Figure 7) and that only a small fraction of GENEVA mosaic subjects have a record of hematological cancer before DNA sampling (2.8%, 95% CI=1.0 – 4.7%). The period between first appearance of detectable clonal mosaicism and incidence of hematological cancer is of interest, but cannot be estimated from our data since mosaicism was present for an unknown period of time prior to DNA sampling. However, the median time of 3.5 years between DNA sampling and hematological cancer diagnosis provides a very rough minimum estimate (range 3.5 months to 10.7 years with N=15; see Figure 7).
